Klimas, Rafael http://orcid.org/0000-0001-5989-2195
Kordes, Anna
Huckemann, Sophie
Gasz, Zornitsa
Philipps, Jörg
Sgodzai, Melissa
Grüter, Thomas
Sevindik, Melis
Schneider-Gold, Christiane
Gold, Ralf
Keyvani, Kathy
Yoon, Min-Suk
Fisse, Anna Lena
Pitarokoili, Kalliopi
Motte, Jeremias
Funding for this research was provided by:
Katholisches Klinikum Bochum gGmbh
Article History
Received: 2 February 2024
Revised: 14 May 2024
Accepted: 16 May 2024
First Online: 29 May 2024
Declarations
:
: Rafael Klimas: received research funding from The LFB Group France and Ruhr-University, Bochum and travel funding from Grifols and Takeda; not related to this work. Anna Kordes, Sophie Huckemann, Zornitsa Gash, Joerg Phillips, Melissa Sgodzai, Thomas Grüter, Melis Sevindik, Christiane Schneider-Gold: no disclosures relevant to the article. Ralf Gold: serves on scientific advisory boards for Teva Pharmaceutical Industries Ltd., Biogen Idec, Bayer Schering Pharma, and Novartis; has received speaker honoraria from Biogen Idec, Teva Pharmaceutical Industries Ltd., Bayer Schering Pharma, and Novartis; serves as editor for Therapeutic Advances in Neurological Diseases and on the editorial boards of Experimental Neurology and the Journal of Neuroimmunology; and receives research support from Teva Pharmaceutical Industries Ltd., Biogen Idec, Bayer Schering Pharma, Genzyme, Merck Serono, and Novartis, none related to this manuscript. Kathy Keyvani: no disclosures relevant to the article. Min-Suk Yoon has received speaker honoraria from CSL Behring and Grifols, a scientific grant from CSL Behring, none related to this manuscript. Anna Lena Fisse: received research funding by Georgius Agricola Stiftung Ruhr and Ruhr-University, Bochum (FoRUM-program), received honoraria and travel grants from Novartis AG, Sanofi and Eisai GmbH, none related to this work. Owns shares of Fresenius SE & Co., Gilead Sciences, Medtronic PLC and Novartis AG. None related to this work. Kalliopi Pitarokoili: received travel funding and speaker honoraria from Biogen Idec, Novartis and Bayer Schering Pharma and funding from the Ruhr-University, Bochum (FORUM-Program), none related to this work. Jeremias Motte: received travel grants from Biogen idec, Novartis AG, Teva and Eisai GmbH, his research is funded by Klaus Tschira Foundation and Ruhr-University, Bochum (FoRUM-program); Hertie foundation; Biogen idec; Deutsche Forschungsgemeinschaft (DFG); none related to this work.
: All procedures performed in studies involving human participants were in accordance with the ethical standard of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendment or comparable ethical standards. The study was approved by the local ethics committee.
: The patients gave spoken and written consent for publication and participation in the study.